MP0317 in Combination With Chemoimmunotherapy in First Line Treatment for Patients With Advanced Biliary Tract Carcinoma
Phase 2
Not yet recruiting
- Conditions
- Advanced Biliary Tract Carcinoma
- Interventions
- Procedure: CT-ScanDrug: MP0317 + Gemcitabine + Cisplatine + DurvalumabDrug: Gemcitabine + Cisplatin + Durvalumab
- First Posted Date
- 2025-06-25
- Last Posted Date
- 2025-06-25
- Lead Sponsor
- Centre Hospitalier Universitaire de Besancon
- Target Recruit Count
- 75
- Registration Number
- NCT07036380
- Locations
- 🇫🇷
CHU de Besançon, Besancon, France
🇫🇷Centre georges-François Leclerc, Dijon, France
🇫🇷CHU de Grenoble, Grenoble, France
Prognosis of Cirrhotic Patients Admitted to the General Intensive Care Unit Between 2014 and 2024: a Regional Retrospective Multicentre Cohort Study
Not yet recruiting
- Conditions
- CirrhosisIntensive Care MedicineAcute on Chronic Liver Failure(ACLF)
- First Posted Date
- 2025-04-29
- Last Posted Date
- 2025-04-29
- Lead Sponsor
- Centre Hospitalier Universitaire de Besancon
- Target Recruit Count
- 500
- Registration Number
- NCT06948565
- Locations
- 🇫🇷
CHU de Besançon, Besançon, France
Relation Between Insulinoresistance and Neutrophile to Lymphocyte Ratio in Cardiac Surgery.
Completed
- Conditions
- Insulin ResistanceCardiac Surgery Requiring Cardiopulmonary BypassNeutrophil Lymphocyte Ratio
- First Posted Date
- 2025-04-25
- Last Posted Date
- 2025-04-25
- Lead Sponsor
- Centre Hospitalier Universitaire de Besancon
- Target Recruit Count
- 211
- Registration Number
- NCT06945536
- Locations
- 🇫🇷
CHU Besançon, Besançon, France
PRECEE2 Perinatal Research
Not yet recruiting
- Conditions
- Pregnancy Complications
- First Posted Date
- 2025-04-18
- Last Posted Date
- 2025-04-18
- Lead Sponsor
- Centre Hospitalier Universitaire de Besancon
- Target Recruit Count
- 30000
- Registration Number
- NCT06933719
Evaluation of the Feasibility of a Study Comparing Local Anesthesia and General Anesthesia in Conservative Surgery for Breast Cancer
Not Applicable
Not yet recruiting
- Conditions
- Breast Cancer
- First Posted Date
- 2025-04-04
- Last Posted Date
- 2025-04-04
- Lead Sponsor
- Centre Hospitalier Universitaire de Besancon
- Target Recruit Count
- 60
- Registration Number
- NCT06910280
- Locations
- 🇫🇷
CHU de Besancon, Besancon, Franche Comte, France
Study of Emotional Regulation and Underlying Prefrontal Activity in Binge Eating Disorder
Not Applicable
Not yet recruiting
- Conditions
- Binge-Eating DisorderEmotional EatingHealthy Volunteers
- First Posted Date
- 2025-03-07
- Last Posted Date
- 2025-04-20
- Lead Sponsor
- Centre Hospitalier Universitaire de Besancon
- Target Recruit Count
- 80
- Registration Number
- NCT06864065
- Locations
- 🇫🇷
UFC - UFR Santé, Besançon, France
🇫🇷CHU de Besançon, Besançon, France
🇫🇷CHU de Dijon, Dijon, France
Prognostic Value of a Multidimensional Assessment for Survival in Elderly Patients With CKD 4B/5
Not yet recruiting
- Conditions
- Chronic Kidney Disease Stage 5Chronic Kidney Disease Stage 4B
- First Posted Date
- 2025-02-13
- Last Posted Date
- 2025-05-01
- Lead Sponsor
- Centre Hospitalier Universitaire de Besancon
- Target Recruit Count
- 390
- Registration Number
- NCT06825234
- Locations
- 🇫🇷
Besançon University Hospital, Besançon, France
🇫🇷Tours University Hospital, Tours, France
Clinical Efficacy of Platelet Transfusion
Not yet recruiting
- Conditions
- ThrombocytopaeniaHaematological Malignancies
- First Posted Date
- 2025-02-03
- Last Posted Date
- 2025-02-03
- Lead Sponsor
- Centre Hospitalier Universitaire de Besancon
- Target Recruit Count
- 343
- Registration Number
- NCT06805097
- Locations
- 🇫🇷
CHU Besançon, Besançon, France
Identification of Innovative Biomarkers to Predict Outcomes in Hepatocellular Carcinoma Treated With Tremelimumab and Durvalumab
Not Applicable
Not yet recruiting
- Conditions
- Hepatocellular Carcinoma
- First Posted Date
- 2025-01-28
- Last Posted Date
- 2025-04-04
- Lead Sponsor
- Centre Hospitalier Universitaire de Besancon
- Target Recruit Count
- 120
- Registration Number
- NCT06796114
- Locations
- 🇫🇷
CHU de Besançon, Besancon, France
🇫🇷CH de Chalon sur Saône, Chalon-sur-Saône, France
🇫🇷CHU Grenoble, Grenoble, France
Optimal Dose of Anti-lymphocyte Globulin in Kidney Transplant Recipients With Low Immunological Risk
Phase 1
Not yet recruiting
- Conditions
- Renal Transplantation
- Interventions
- Drug: Grafalon® administered during 5 consecutive days at 2 mg/kg/jDrug: Grafalon® administered during 5 consecutive days at 1 mg/kg/jDrug: Grafalon® administered during 5 consecutive days at 0,5 mg/kg/j
- First Posted Date
- 2024-12-20
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- Centre Hospitalier Universitaire de Besancon
- Target Recruit Count
- 18
- Registration Number
- NCT06744400